Chen Jiangtao, Younusi Aikebaier, Cao Li, Xu Leilei, Zhou Yijun, Zhen Tian, Song Xinghua
Clin Lab. 2015;61(8):1077-81. doi: 10.7754/clin.lab.2015.141222.
To investigate the serum levels of N-terminal telopeptide of type I collagen (NTx) and tartrate-resistant acid phosphatase 5b (TRACP5b) in giant cell tumor of bone (GCT) patients and the clinical implications.
56 GCT patients (29 males and 27 females, 15 to 60 years old with a median age of 28.0 years old) with clinicopathological characteristics of GCT were enrolled in the Department of Bone Cancer, the Affiliated Cancer Hospital of Xinjiang Medical University from October 2008 to October 2014. The enzyme-linked immunosorbent assay (ELISA) was used to detect the serum levels of NTx and TRACP5b in the patients.
Compared with 21 patients who had a GCT of < 5 cm, the serum levels of NTx and TRACP5b in the 35 patients with a GCT of ≥ 5 cm were significantly increased (p < 0.05). Compared with those GCT patients who had a grade I tumor, the levels of NTx and TRACP5b in grade II patients were not increased (p > 0.05), but the levels of NTx and TRACP5b were significantly increased in grade III patients (p < 0.05). Moreover, compared with the patients in histologic stage I, the levels of NTx and TRACP5b in stage II GCT patients were not increased (p > 0.05), whereas the levels in grade III patients were significantly increased (p < 0.05). In addition, the location of the tumor had a significant effect on the serum levels of NTx and TRACP5b (p < 0.05).
Our study suggests that serum NTx and TRACP5b are sensitive and simple biomarkers to indicate aberrant bone metabolism in GCT patients, and they may have a clinical significance in GCT diagnosis. Combined examination for both markers helps in the classification of clinicopathological stages of GCT patients and in the prognosis of the disease.
探讨骨巨细胞瘤（GCT）患者血清I型胶原N端肽（NTx）和抗酒石酸酸性磷酸酶5b（TRACP5b）水平及其临床意义。
选取2008年10月至2014年10月在新疆医科大学附属肿瘤医院骨肿瘤科就诊的56例具有GCT临床病理特征的患者（男29例，女27例，年龄15至60岁，中位年龄28.0岁）。采用酶联免疫吸附测定（ELISA）法检测患者血清NTx和TRACP5b水平。
与21例肿瘤直径<5 cm的GCT患者相比，35例肿瘤直径≥5 cm的GCT患者血清NTx和TRACP5b水平显著升高（p<0.05）。与I级肿瘤的GCT患者相比，II级患者的NTx和TRACP5b水平未升高（p>0.05），但III级患者的NTx和TRACP5b水平显著升高（p<0.05）。此外，与组织学I期患者相比，II期GCT患者的NTx和TRACP5b水平未升高（p>0.05），而III级患者的水平显著升高（p<0.05）。另外，肿瘤部位对血清NTx和TRACP5b水平有显著影响（p<0.05）。
我们的研究表明，血清NTx和TRACP5b是指示GCT患者骨代谢异常的敏感且简单的生物标志物，它们可能在GCT诊断中具有临床意义。联合检测这两种标志物有助于GCT患者临床病理分期的分类及疾病的预后评估。
